SCHEMBL30295914

SCHEMBL30295914

CN(CCO)c1ncnc2c1c(-c1cccc(Cl)c1)cn2COCC[Si](C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ STK4 Q13043 5/20 0.54
▸ STK3 Q13188 5/20 0.54
▸ LRRK2 Q5S007 2/20 0.54
▸ ADK P55263 2/20 0.41
▸ TP53 P04637 3/20 0.39
▸ SRC P12931 5/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ EGFR P00533 2/20 0.36
▸ ABL2 P42684 2/20 0.36
▸ KDR P35968 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ SLC6A9 P48067 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295769 0.92 STK4 (0.53) STK4STK3LRRK2ADKTP53
SCHEMBL30295858 0.90 STK4 (0.55) STK4STK3LRRK2ADKTP53
SCHEMBL30295798 0.89 STK4 (0.56) STK4STK3LRRK2ADKTP53
SCHEMBL30295768 0.85 STK4 (0.45) STK4STK3LRRK2ADKTP53
SCHEMBL31301813 0.84 STK4 (0.44) STK4STK3LRRK2ADKTP53
SCHEMBL30295700 0.83 SRC (0.42) STK4STK3LRRK2ADKTP53
SCHEMBL30295881 0.81 STK4 (0.44) STK4STK3LRRK2ADKTP53
SCHEMBL15401643 0.80 LRRK2 (0.51) LRRK2ADKSRCRXFP1ABL1
SCHEMBL30296033 0.80 STK3 (0.54) STK4STK3LRRK2ADKTP53
SCHEMBL30295783 0.77 ADK (0.50) STK4STK3LRRK2ADKTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 — — US disclosed
WO-2023055731-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 STK4 2/4885STK3 1/4885LRRK2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback